The evaluation of the avb6 integrin as a biomarkers and therapeutic target for idiopathic pulmonary fibrosis

avb6整合素作为特发性肺纤维化生物标志物和治疗靶点的评估

• 批准号: G0901226/1
• 负责人: Gisli Jenkins
• 金额: $ 53.45万
• 依托单位: University of Nottingham
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2010
• 资助国家: 英国
• 起止时间: 2010 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0901226%2F1
• 关键词: evaluation; avb6; integrin; biomarkers; therapeutic

Idiopathic pulmonary fibrosis (IPF) is a disease where the fine, delicate structure of the lungs is replace by a hard, concrete-like substance called fibrous matrix. This prevents the normal functions of the lung, such as the transfer of oxygen from the air to the body, it also leads to irritation and persistent cough. The speed at which this concrete-like matrix is deposited in the lung varies between different people, but ultimately leads to death. Unfortunately it is difficult to predict who will get worse quickly, and who will get worse slowly. Furthermore, there are no treatments that can improve the outlook for people with IPF at the current time. The aim of this study is to develop a biological test that can predict which people with IPF are going to have slowly progressive disease compared with rapidly progressive disease. More importantly these biological tests will hopefully be able to be used to show whether a current, or new treatment, is working in an individual patient. This information will help patients plan their future when the receive a diagnosis of IPF and will help in the development of new treatments for this condition, which are so urgently sought.

特发性肺纤维化（IPF）是一种疾病，其中肺的精细，微妙的结构被称为纤维基质的坚硬，混凝土样物质取代。这阻止了肺的正常功能，例如氧气从空气中转移到身体，它还导致刺激和持续咳嗽。这种混凝土样基质沉积在肺部的速度因人而异，但最终导致死亡。不幸的是，很难预测谁会迅速恶化，谁会慢慢恶化。此外，目前没有治疗方法可以改善IPF患者的前景。这项研究的目的是开发一种生物学检测方法，可以预测哪些IPF患者的疾病进展缓慢，而哪些患者的疾病进展迅速。更重要的是，这些生物学测试将有望用于显示当前或新的治疗方法是否适用于个体患者。这些信息将帮助患者在接受IPF诊断时规划他们的未来，并将有助于开发这种疾病的新治疗方法，这是迫切需要的。